Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in three upcoming conferences:

  • BTIG Virtual Biotechnology Conference 2020
    Date:
    Monday, August 10, 2020
    Presentation Time: 12:00 p.m. ET / 9:00 a.m. PT
  • 2020 Wedbush PacGrow Healthcare Virtual Conference
    Date:
    Wednesday, August 12, 2020
    Presentation Time: 2:20 p.m. ET / 11:20 a.m. PT
  • Canaccord Genuity 40th Annual Growth Conference
    Date:
    Thursday, August 13, 2020
    Panel Time: 1:00 p.m. ET / 10:00 a.m. PT

A live webcast of the presentations at the BTIG and Wedbush conferences will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Replays will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 17 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005977/en/

Xencor Inc. Stock

€19.60
4.810%
A very strong showing by Xencor Inc. today, with an increase of €0.90 (4.810%) compared to yesterday's price.
We see a rather positive sentiment for Xencor Inc. with 14 Buy predictions and 1 Sell predictions.
As a result the target price of 31 € shows a very positive potential of 58.16% compared to the current price of 19.6 € for Xencor Inc..
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments